Eurocor Tech - Life Sciences Technologies Interventional Cardiology Devices Endovascular Therapies

Dediacted to Your heart.
Life Sciences Technology.
Coronary stent technologies and special cardiovascular and endovascluar devices made in Europe for the world.

Eurocor Enters into Licensing Agreement with Biosensors for Drug-eluting Balloon Range

Date: 2013/05/31

Eurocor has undertaken to no longer use one sentence which was contained in the initial version of the press release. The sentence which was correspondingly amended is marked in bold in the new version of the press release below.

Eurocor GmbH, a group company of Opto Circuits (India) Ltd. (Bloomberg: OPTC IN; Reuters: OPTO. NS; NSE OPTOCIRCUI; BSE: 532391), has entered into a licensing agreement with Biosensors International Group, Ltd. (“Biosensors” or the “Company”, Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices. The agreement pertains to the former’s Drug Eluting Balloon (DEB) technology and the related German utility model (DE 20 2010 017 248) as well as several pending patent applications in relation to the treatment of both coronary and peripheral artery disease (European Patent application EP 2421572 and other national patent applications). As a first step in this process, an Original Equipment Manufacturer (OEM) arrangement is being implemented, whereby Biosensors will market and sell, under its own brand, DEBs manufactured by Eurocor.
Both agreements will involve three Biosensors-branded DEBs: BioStream™; BioPath™ 014; and BioPath™ 035. All three devices are drug-eluting balloon dilatation catheters designed for percutaneous transluminal angioplasty (PTA): BioStream has been developed for use in coronary arteries; the two BioPath DEBs have been optimized for the treatment of patients with peripheral arterial disease. BioPath 035 is intended for peripheral intervention above the knee and BioPath 014 for infrapopliteal intervention below the knee.

All three DEBs feature Eurocor’s coating technology delivering paclitaxel, an antirestenotic drug proven in DEB applications. The coating technology has been proven in several clinical studies performed by Eurocor, including the global Valentine I and II studies. The proprietary coating employed in these DEB products is capable of delivering the antirestenotic drug consistently during very brief inflation times, while also minimizing washout of the drug during delivery and placement of the DEB.

“We are delighted to have acquired a new range of DEBs as a result of this licensing agreement with Eurocor”, commented Jeffrey B. Jump, President of Biosensors’ Cardiovascular Division. “These innovative devices will complement our existing portfolio of cardiac stents, and facilitate our entry into the peripheral vascular disease market.”
Following CE Mark approval currently anticipated within the next six weeks, BioStream, BioPath 014 and BioPath 035 will be launched in major European markets and selected regions in the Middle East, Africa and Asia.

“This agreement is further validation for Eurocor’s DEB products. There is considerable scope for global expansion within this rapidly-growing sector of the interventional devices market,” added Dr. Antonino Laudani, COO of Eurocor GmbH. “We are looking forward to working closely with Biosensors to further the process of establishing Eurocor as one of the leading global providers of innovative DEB products”.
"This arrangement with Eurocor is a positive development in the broadening of our cardiovascular business”, concluded Dr Jack Wang, CEO of Biosensors. “It also marks the first step in our expansion into the peripheral business."

PR Eurocor enters into license agreement